Quetiapine monotherapy for bipolar depression

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 A, 2008, Pages 21-31

  Thase, Michael E ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Bipolar disorder; Depression; Manic depression; Mood stabilizer; Quetiapine

Indexed keywords

FLUOXETINE; LITHIUM; OLANZAPINE; QUETIAPINE; VALPROIC ACID;

ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETHARGY; MANIA; OUTCOME ASSESSMENT; QUALITY OF LIFE; RAPID CYCLING BIPOLAR DISORDER; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

EID: 41549159758     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s1162     Document Type: Article

References (58)

1. AstraZeneca. Seroquel® (quetiapine fumarate) tablets: prescribing information [online]. Accessed 2007 April 18. URL: http://www.seroquel.com
2. Bauer MS, Mitchner L. 2004. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry, 161:3-18.
3. Becker PM. 2006. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol, 8:367-75.
4. Brown EB, McElroy SL, Keck PE Jr, et al. 2006. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry, 67:1025-33.
5. Burton SC. 2005. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract, 11:369-78.
6. Calabrese JR, Bowden CL, Sachs GS, et al. 1999. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry, 60:79-88.
7. Calabrese JR, Keck PE Jr, Macfadden W, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry, 162:1351-60.
8. Depp CA, Davis CE, Mittal D, et al. 2006. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry, 67:215-21.
9. Dilsaver SC, Chen YW, Swann AC, et al. 1997. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res, 73:47-56.
10. Endicott J, Rajagopalan K, Minkwitz M, et al. 2007. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol, 22:29-37.
11. Fagiolini A, Frank E, Scott JA, et al. 2005. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord, 7:424-30.
12. Frank E, Cyranowski JM, Rucci P, et al. 2002. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry, 59:905-11.
13. Frye MA, Ketter TA, Kimbrell TA, et al. 2000. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol, 20:607-14.
14. Gaudiano BA, Miller IW. 2005. Anxiety disorder comobidity in Bipolar I Disorder: relationship to depression severity and treatment outcome. Depress Anxiety, 21:71-7.
15. Goldberg JF, Truman CJ. 2003. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord, 5:407-20.
16. Goodwin GM, Malhi GS. 2007. What is a mood stabilizer? Psychol Med, In Press.
17. Grunze H. 2005. Reevaluating therapies for bipolar depression. J Clin Psychiatry, 66(Suppl 5):17-25.
18. Henry C, Van den Bulke D, Bellivier F, et al. 2003. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry, 64:331-5.
19. Hirschfeld RM. 2004. Bipolar depression: the real challenge. Eur Neuropsychopharmacol, 14(Suppl 2):S83-8.
20. Hirschfeld RM, Weisler RH, Raines SR, et al. 2006. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 67:355-62.
21. Judd LL, Akiskal HS, Schettler PJ, et al. 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry, 59:530-7.
22. Judd LL, Akiskal HS, Schettler PJ, et al. 2003. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry, 60:261-9.
23. Judd LL, Akiskal HS, Schettler PJ, et al. 2005. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry, 62:1322-30.
24. Kasper SF. 2004. Living with bipolar disorder. Expert Rev Neurother, 4; 6(Suppl 2):S9-15.
25. Keck PE Jr. 2005. Bipolar depression: a new role for atypical antipsychotics? Bipolar Disord, 7(Suppl 4):34-40.
26. Keller MB. 2006. Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry, 67(Suppl 1):5-7.
27. Ketter TA, Calabrese JR. 2002. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry, 63:146-51.
28. McIntyre RS, Soczynska JK, Bottas A, et al. 2006. Anxiety disorders and bipolar disorder: a review. Bipolar Disord, 8:665-76.
29. Michalak EE, Yatham LN, Lam RW. 2005. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes, 3:72.
30. Milev R, Abraham G, Zaheer J. 2006. Add-on quetiapine for bipolar depression: a 12-month open-label trial. Can J Psychiatry, 51:523-30.
31. Mitchell PB, Malhi GS. 2004. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord, 6:530-9.
32. Mitchell PB, Ball JR, Best JA, et al. 2006. The management of bipolar disorder in general practice. Med J Aust, 184:566-70.
33. Muller MJ, Himmerich H, Kienzle B, et al. 2003. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord, 77:255-60.
34. Murray CJ, Lopez AD. 1997. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet, 349:1347-52.
35. Nemeroff CB. 2005. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry, 66(Suppl 8):13-21.
36. Ogilvie AD, Morant N, Goodwin GM. 2005. The burden on informal caregivers of people with bipolar disorder. Bipolar Disord, 7(Suppl 1):25-32.
37. Ostacher MJ. 2006. The evidence for antidepressant use in bipolar depression. J Clin Psychiatry, 67(Suppl 11): 18-21
38. Perlick DA, Rosenheck RA, Clarkin JF, et al. 2004. Impact of family burden and affective response on clinical outcome among patients with bipolar disorder. Psychiatr Serv, 55:1029-35.
39. Pierre JM. 2005. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf, 28:191-208.
40. Post RM. 2005. The impact of bipolar depression. J Clin Psychiatry, 66(Suppl 5):5-10.
41. Post RM, Denicoff KD, Leverich GS, et al. 2003. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry, 64:680-90.
42. Sachs GS. 2005. What is a mood stabilizer? Clin Appr Bipolar Disord, 4:3.
43. Sachs GS, Nierenberg AA, Calabrese JR, et al. 2007. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med, 356:1711-22.
44. Schneck CD. 2006. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry, 67(Suppl 11):22-7.
45. Seeman P. 2002. Atypical antipsychotics: mechanism of action. Can J Psychiatry, 47:27-38.
46. Simon NM, Otto MW, Wisniewski SR, et al. 2004a. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry, 161:2222-9.
47. Simon NM, Otto MW, Weiss RD, et al. 2004b. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol, 24:512-20.
48. Thase ME. 2005. Bipolar depression: issues in diagnosis and treatment. Harv Rev Psychiatry, 13:257-71.
49. Thase ME, Macfadden W, Weisler RH, et al. 2006. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol, 26:600-9.
50. Tohen M, Vieta E, Calabrese J, et al. 2003. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry, 60:1079-88.
51. Tort AB, Souza DO, Lara DR. 2006. Theoretical insights into the mechanism of action of atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry, 30:541-8.
52. Vieta E. 2005. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol, 20:225-36.
53. Vieta E, Calabrese J, Goikolea J, et al; for the BOLDER Study Group. 2007. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord, 9:413-25.
54. Vojta C, Kinosian B, Glick H, et al. 2001. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry, 42:190-5.
55. Vornik LA, Hirschfeld RM. 2005. Bipolar disorder: quality of life and the impact of atypical antipsychotics. Am J Manag Care, 11(Suppl 9): S275-80.
56. Yatham LN, Kennedy SH, O'Donovan C, et al. 2005. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord, 7(Suppl 3):5-69.
57. Yatham LN, Kennedy SH, O'Donovan C, et al. 2006. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord, 8:721-39.
58. Zornberg GL, Pope HG Jr, 1993. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol, 13:397-408.